Syros Pharmaceuticals (NASDAQ:SYRS) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) in a report released on Thursday morning. The firm issued a hold rating on the stock.

Other research analysts have also issued research reports about the stock. JMP Securities reaffirmed a buy rating and issued a $16.00 price target on shares of Syros Pharmaceuticals in a research note on Monday, December 12th. HC Wainwright reissued a buy rating and issued a $15.00 price objective on shares of Syros Pharmaceuticals in a research report on Friday, March 3rd. Oppenheimer cut their price objective on shares of Syros Pharmaceuticals from $15.00 to $13.00 and set an outperform rating on the stock in a research report on Thursday, March 2nd. Finally, Piper Sandler cut their price objective on shares of Syros Pharmaceuticals from $27.00 to $20.00 and set an overweight rating on the stock in a research report on Thursday, January 5th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $32.80.

Syros Pharmaceuticals Trading Down 5.4 %

Shares of SYRS opened at $2.82 on Thursday. The company has a quick ratio of 6.87, a current ratio of 6.87 and a debt-to-equity ratio of 0.32. Syros Pharmaceuticals has a twelve month low of $2.82 and a twelve month high of $14.30. The firm’s 50 day moving average price is $4.15 and its two-hundred day moving average price is $4.62.

Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) last announced its quarterly earnings results on Thursday, March 2nd. The company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.01). Syros Pharmaceuticals had a negative net margin of 485.12% and a negative return on equity of 134.48%. The company had revenue of ($0.75) million during the quarter, compared to the consensus estimate of $3.28 million. As a group, research analysts forecast that Syros Pharmaceuticals will post -4.41 earnings per share for the current year.

Institutional Trading of Syros Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Denali Advisors LLC bought a new stake in Syros Pharmaceuticals during the fourth quarter worth $28,000. Edmond DE Rothschild Holding S.A. bought a new stake in Syros Pharmaceuticals during the third quarter worth $28,000. Private Advisor Group LLC bought a new stake in Syros Pharmaceuticals during the first quarter worth $29,000. Sawtooth Solutions LLC acquired a new position in shares of Syros Pharmaceuticals in the first quarter valued at $29,000. Finally, Prudential Financial Inc. acquired a new position in shares of Syros Pharmaceuticals in the second quarter valued at $32,000. 48.77% of the stock is owned by institutional investors.

About Syros Pharmaceuticals

(Get Rating)

Syros Pharmaceuticals, Inc engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.